文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

曲奥舒凡对比减低强度白消安改善老年急性髓系白血病及骨髓增生异常综合征患者异基因造血细胞移植结局:一项前瞻性随机试验的最终分析

Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
PubMed 文献 · Am J Hematol · 2022-06-08

这项III期随机试验在570例老年或合并症急性髓系白血病(AML)或骨髓增生异常综合征(MDS)患者中,比较曲奥舒凡与减低强度白消安预处理后的无事件生存(EFS)。最终分析显示曲奥舒凡组36个月EFS率59.5% vs 白消安组49.7%(HR 0.64,95%CI 0.49-0.84,P=0.0006),总生存亦更优。

要点

  • 曲奥舒凡组36个月EFS率59.5%,白消安组49.7%,HR 0.64(95%CI 0.49-0.84),P=0.0006。
  • 曲奥舒凡组36个月总生存率66.8%,白消安组56.3%,HR 0.64(95%CI 0.48-0.87),P=0.0037。
  • 事后分析显示曲奥舒凡方案似乎尤其适合老年AML和MDS患者。

核心结论

  • 在老年或合并症AML/MDS患者中,曲奥舒凡预处理较减低强度白消安显著改善无事件生存和总生存。
  • 事后分析显示曲奥舒凡方案似乎尤其适合老年AML和MDS患者。

研究设计与样本

  • III期前瞻性随机试验,最终分析纳入全部570例随机患者,随访时间已延长。
  • 纳入HCT特异性合并症指数>2或年龄≥50岁的AML或MDS患者,按1:1随机分配至静脉氟达拉滨联合曲奥舒凡(30 g/m² IV)或白消安(6.4 mg/kg IV),按疾病风险组、供者类型和参与机构分层。
  • 主要终点为无事件生存(EFS),事件包括疾病复发、移植失败或任何原因死亡。

主要发现

  • 患者中位年龄60岁;曲奥舒凡组36个月EFS率59.5%(95%CI 52.2-66.1),白消安组49.7%(95%CI 43.3-55.7),HR 0.64(95%CI 0.49-0.84),P=0.0006。
  • 曲奥舒凡组36个月总生存率66.8%,白消安组56.3%,HR 0.64(95%CI 0.48-0.87),P=0.0037。
  • 事后分析显示上述差异与确证性中期分析结果一致。

关键数值与推荐

  • 曲奥舒凡剂量为30 g/m² IV,白消安剂量为6.4 mg/kg IV,均联合静脉氟达拉滨。
  • 分层因素包括疾病风险组、供者类型和参与机构。

临床怎么用

  • 作者认为曲奥舒凡方案似乎尤其适合老年AML和MDS患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged ≥50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m2 IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Beelen DW, Stelljes M, Reményi P, et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. Am J Hematol. 2022. PMID: 35617104. doi:10.1002/ajh.26620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。